News
Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
- USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally
- Round led by Venrock Healthcare Capital Partners with participation from other new investors Wellington Management and Ascenta Capital, as well as existing investors
MUNICH, GERMANY, October 15, 2025 – Tubulis today announced the successful closing of a €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Partners.